Agarwal Amit, Pradhan Roma, Kumari Niraj, Krishnani Narendra, Shukla Pooja, Gupta Sushil Kumar, Chand Gyan, Mishra A, Agarwal Gaurav, Verma Ashok Kumar, Mishra Saroj Kanta
Department of Endocrine Surgery, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, 226014, India.
Department of Pathology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
World J Surg. 2016 Mar;40(3):607-14. doi: 10.1007/s00268-015-3380-2.
The clinical entity of large parathyroid adenomas (LPTAs) has not been well defined. It is speculated that LPTAs would have biochemical, histological, and molecular characteristics different from small adenomas. Our study aimed to find out occurrence of atypia and carcinomas in large parathyroid lesions and the presence of distinct molecular abnormalities in LPTAs.
We divided the parathyroid lesions into large (>7 g, i.e., LPTAs) and small (<7 g) adenomas. We performed parafibromin, APC (adenomatous polyposis coli), galectin 3, and PGP9.5 (protein gene product 9.5) analysis by immunohistochemistry in adenomas without atypia, atypical adenomas, and carcinomas.
Mean serum calcium, alkaline phosphatase, and intact PTH were significantly higher in large parathyroid tumor group. The presence of both atypical adenoma and carcinoma was higher in large parathyroid tumor group. There was higher percentage of atypia in patients with LPTAs >10 g (33%), and 68% of tumors showed at least one marker suggestive of malignancy in this group. Detailed analysis of immunohistochemical features of LPTA >10 g revealed that six patients showed complete loss of parafibromin immunoreactivity (out of these four showed atypia), while seven showed partial loss. In histopathologically proven malignancy (n = 9), six patients showed complete loss of parafibromin staining, 5 (55%) APC negativity, and 45% showed both galectin 3 and PGP9.5 positivity. Three out of these showed all IHC markers s/o malignancy, and all of them had evidence of metastases or recurrence. 32% of atypical adenoma and 13% of atypical adenoma showed complete loss of parafibromin staining, however none developed metastases or recurrence in follow-up (median follow-up 40 months). Loss of parafibromin staining (complete or partial) was higher in LPTA group (56%) than that in small adenoma (39%); however, it was not statistically significant. APC, galectin 3, and PGP9.5 markers suggestive were higher in LPTA group but were not significant.
LPTAs may show some morphological and immunohistochemical features suggestive of malignancy and can be considered a separate entity. However, the immunohistochemical markers are unable to clearly segregate those LPTAs that may show premalignant potential. Further, we would like to recommend that LPTAs showing complete parafibromin loss together with atypia should be kept under close follow-up.
大甲状旁腺腺瘤(LPTA)的临床实体尚未得到明确界定。据推测,LPTA在生化、组织学和分子特征方面与小腺瘤不同。我们的研究旨在找出大甲状旁腺病变中异型性和癌的发生率,以及LPTA中独特分子异常的存在情况。
我们将甲状旁腺病变分为大腺瘤(>7克,即LPTA)和小腺瘤(<7克)。我们通过免疫组织化学对无异型性的腺瘤、非典型腺瘤和癌进行帕拉纤维蛋白、APC(腺瘤性息肉病蛋白)、半乳糖凝集素3和PGP9.5(蛋白基因产物9.5)分析。
大甲状旁腺肿瘤组的平均血清钙、碱性磷酸酶和完整甲状旁腺激素水平显著更高。大甲状旁腺肿瘤组中非典型腺瘤和癌的发生率更高。>10克的LPTA患者中异型性百分比更高(33%),该组中68%的肿瘤至少有一个提示恶性的标志物。对>10克的LPTA的免疫组织化学特征进行详细分析发现,6例患者帕拉纤维蛋白免疫反应性完全丧失(其中4例有异型性),7例部分丧失。在组织病理学证实为恶性的病例(n = 9)中,6例患者帕拉纤维蛋白染色完全丧失,5例(55%)APC阴性,45%同时显示半乳糖凝集素3和PGP9.5阳性。其中3例显示所有免疫组化标志物提示恶性,且均有转移或复发证据。32%的非典型腺瘤和13%的非典型腺瘤显示帕拉纤维蛋白染色完全丧失,但随访期间均未发生转移或复发(中位随访40个月)。LPTA组中帕拉纤维蛋白染色丧失(完全或部分)高于小腺瘤组(39%),但差异无统计学意义。LPTA组中提示APC、半乳糖凝集素3和PGP9.5的标志物更高,但无统计学意义。
LPTA可能表现出一些提示恶性的形态学和免疫组织化学特征,可被视为一个独立的实体。然而,免疫组化标志物无法明确区分那些可能具有恶变潜能的LPTA。此外,我们建议对显示帕拉纤维蛋白完全丧失且伴有异型性的LPTA进行密切随访。